News

FDA Recommends Abeona’s EB-101 Gene Therapy to Advance Toward Phase 3 Trial

The U.S. Food and Drug Administration (FDA) recently recommended Abeona Therapeutics accelerate the clinical development program of its gene therapy candidate EB-101 for the treatment of patients with recessive dystrophic epidermolysis bullosa (RDEB), also known as “butterfly skin” syndrome. With the recommendation, which came in a recent Type-C meeting with the…

EMA Grants TXA127 Orphan Drug Status to Treat Epidermolysis Bullosa

The European Medicines Agency (EMA) recently granted Tarix Orphan’s lead investigational product TXA127 orphan drug status for the treatment of epidermolysis bullosa (EB). Orphan drug status is granted by regulatory agencies to drugs in development for the treatment of rare diseases, and where the pharmaceutical company will profit…

Trial Evaluating Diacerein 1% Ointment as EBS Treatment Enrolls First Patient

The first patient has enrolled in a clinical trial evaluating both the efficacy and safety of diacerein 1% ointment (CCP-020) in treating epidermolysis bullosa simplex (EBS), Castle Creek Pharmaceuticals recently announced. The company’s Phase 2/3 DELIVERS clinical trial (NCT03154333) is currently recruiting participants. CCP-020 is a small molecule, engineered to…

FDA Grants Rare Pediatric Disease Designation to EB-101 as a Treatment for Blistering Skin Disorder

The U.S. Food and Drug Administration has granted a Rare Pediatric Disease Designation to EB-101,  Abeona Therapeutics’ treatment for the inherited skin disease epidermolysis bullosa, or EB. Importantly, the designation also covers a severe form of the blistering and open-wound disorder known as recessive dystrophic epidermolysis bullosa, or RDEB. The FDA…